Abstract
Background Long-term catheterization facilitates continuous bacteriuria, for which the clinical significance is unclear. The objectives of this study were to determine the clinical presentation, epidemiology, and dynamics of bacteriuria in a cohort of catheterized nursing home residents.
Methods Prospective weekly urine collection, culture, urinalysis, chart review, and assessment of possible signs and symptoms of infection for 19 study participants over 260 weeks. All bacteria ≥103 cfu/ml were isolated, identified, and subjected to select antimicrobial testing.
Results From 234 urine samples, 1,092 bacteria were isolated and 286 (26%) were resistant to a tested antimicrobial. 226 urines were polymicrobial (97%), with an average of 4.7 isolates per weekly specimen. 233 urines (99%) exhibited >103 CFU/ml, 220 (94%) exhibited abnormal urinalysis, 77 (33%) were associated with at least one sign or symptom of infection, 51 (22%) met a standardized definition of CAUTI, and 3 (1%) had a corresponding caregiver diagnosis of CAUTI. Bacteriuria composition was remarkably stable, but catheter changes and antimicrobial treatment resulted in a net increase of 1.9 and 0.3 isolates per participant, respectively, and represented a source of new acquisition of antimicrobial resistant bacteria.
Conclusions Catheterized individuals exhibit a high baseline prevalence of bacteriuria involving pathogenic bacteria and potential indicators of infection. Bacteriuria composition is largely polymicrobial and stable, and includes organisms previously considered to be urine culture contaminants. However, catheter changes and antimicrobial treatment may do more harm than good in this patient population. Funding: This work was supported by the NIH (R00 DK105205, R01 DK123158, UL1 TR001412)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was an observational study without any intervention
Funding Statement
This work was supported by the National Institutes of Health via the National Institute of Diabetes Digestive and Kidney Diseases [R00 DK105205 and R01 DK123158 to C.E.A.] and the National Center for Advancing Translational Sciences (UL1 TR001412 to the University at Buffalo). The sponsors were not involved in the study design, methods, subject recruitment, data collections, analysis, or preparation of the paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University at Buffalo Institutional Review Board (STUDY00002526) and complied with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are provided within the manuscript and supplemental files.
